Macon, GA, United States
Macon, GA, United States

Mercer University is a private, coeducational university with its main campus in Macon, Georgia, United States.Mercer enrolls more than 8,500 students in 12 colleges and schools: liberal arts, business, engineering, education, music, continuing and professional studies, law, theology, medicine, pharmacy, nursing, and health professions.Mercer has three campuses: the main campus in Macon, a graduate and professional education campus in Atlanta, and a four-year campus of the School of Medicine in Savannah. Mercer also has regional academic centers in Henry County, Douglas County, Eastman, and Newnan; the Walter F. George School of Law on its own campus in Macon; teaching hospitals in Macon, Savannah, and Columbus; a university press and a performing arts center, the Grand Opera House, in Macon; and the Mercer Engineering Research Center in Warner Robins. The Mercer University Health science Center encompasses Mercer's medical, pharmacy, nursing, and health professions programs in Macon, Atlanta, Savannah, and Columbus.In 2014, US News and World Report ranked Mercer the best value among comprehensive universities in the southern United States. The Princeton Review, which consistently ranks Mercer in the top 10% of colleges and universities in North America, wrote in 2014, "Mercer's exceptional reputation springs from its sound academic programs, excellent faculty, and modern facilities", and in 2005 called the main campus one of the five most beautiful in the United States. Mercer was cited by the Carnegie Foundation for the Advancement of Teaching for its community engagement, and was among the 113 institutions listed on the 2013 President's Higher Education Community Service Honor Roll with Distinction.Mercer has an NCAA Division I athletic program and fields teams in eight men's and ten women's sports; all university-sponsored sports compete in the Southern Conference except women's lacrosse and women's sand volleyball, which are not sponsored by the SoCon, and thus compete in the Atlantic Sun Conference. Wikipedia.


Time filter

Source Type

A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.


Vitamin E-based amphiphilic copolymers are disclosed. Compositions containing vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed. Methods of making vitamin E-based amphiphilic copolymers and/or nanocarriers and methods of using vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed.


News Article | April 26, 2017
Site: www.PR.com

Mansfield, TX, April 26, 2017 --( Dr. Henderson is certified by the American Board of Family Medicine and is affiliated with CHRISTUS Santa Rosa Hospital – Westover Hills in San Antonio, TX. Dr. Henderson believes that God has always blessed her with a serving spirit which naturally extended into her service in family and geriatric medicine. Dr. Henderson is committed to helping her patients enjoy a healthier lifestyle. She works with each one to discuss ways they can make better choices for their health. Specialty - Family Medicine Education & Residency Mercer University, Medical Center of Central Georgia, Residency in Family Medicine Mercer University, Medical Center of Central Georgia, Fellowship in Geriatric Medicine Mansfield, TX, April 26, 2017 --( PR.com )-- Dr. Rashida Henderson is a caring and diligent family physician based in Mansfield, TX. Dr. Henderson attended Louisiana State University, where she received her medical degree. She completed her residency in family medicine and fellowship in geriatric medicine at Mercer University, Medical Center of Central Georgia. She also holds her master’s degree in cellular and molecular biology from Louisiana Tech University.Dr. Henderson is certified by the American Board of Family Medicine and is affiliated with CHRISTUS Santa Rosa Hospital – Westover Hills in San Antonio, TX. Dr. Henderson believes that God has always blessed her with a serving spirit which naturally extended into her service in family and geriatric medicine.Dr. Henderson is committed to helping her patients enjoy a healthier lifestyle. She works with each one to discuss ways they can make better choices for their health.Specialty - Family MedicineEducation & ResidencyMercer University, Medical Center of Central Georgia, Residency in Family MedicineMercer University, Medical Center of Central Georgia, Fellowship in Geriatric Medicine Click here to view the list of recent Press Releases from Mansfield Primary Care Doctors


Patent
Emory University, Mercer University and Union College at Schenectady | Date: 2015-07-08

This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula:


Patent
Emory University, Union College at Schenectady and Mercer University | Date: 2014-05-07

This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula:


Dai X.,Mercer University | Tan C.,Mercer University
Advanced Drug Delivery Reviews | Year: 2015

MicroRNAs (miRNAs) regulate multiple molecular pathways vital for the hallmarks of cancer with a high degree of biochemical specificity and potency. By restoring tumor suppressive miRNAs or ablating oncomiRs, miRNA-based therapies can sensitize cancer cells to conventional cytotoxins and the molecularly targeted drugs by promoting apoptosis and autophagy, reverting epithelial-to-mesenchymal transition, suppressing tumor angiogenesis, and downregulating efflux transporters. The development of miRNA-based therapeutics in combination with small-molecule anticancer drugs provides an unprecedented opportunity to counteract chemoresistance and improve treatment outcome in a broad range of human cancers. This review summarizes the mechanisms and advantages for the combination therapies involving miRNAs and small-molecule drugs, as well as the recent advances in the co-delivery nanocarriers for these agents. © 2014 Elsevier B.V.


Cline S.D.,Mercer University
Biochimica et Biophysica Acta - Gene Regulatory Mechanisms | Year: 2012

How mitochondria process DNA damage and whether a change in the steady-state level of mitochondrial DNA damage (mtDNA) contributes to mitochondrial dysfunction are questions that fuel burgeoning areas of research into aging and disease pathogenesis. Over the past decade, researchers have identified and measured various forms of endogenous and environmental mtDNA damage and have elucidated mtDNA repair pathways. Interestingly, mitochondria do not appear to contain the full range of DNA repair mechanisms that operate in the nucleus, although mtDNA contains types of damage that are targets of each nuclear DNA repair pathway. The reduced repair capacity may, in part, explain the high mutation frequency of the mitochondrial chromosome. Since mtDNA replication is dependent on transcription, mtDNA damage may alter mitochondrial gene expression at three levels: by causing DNA polymerase γ nucleotide incorporation errors leading to mutations, by interfering with the priming of mtDNA replication by the mitochondrial RNA polymerase, or by inducing transcriptional mutagenesis or premature transcript termination. This review summarizes our current knowledge of mtDNA damage, its repair, and its effects on mtDNA integrity and gene expression. This article is part of a special issue entitled: Mitochondrial Gene Expression. © 2012 Elsevier B.V.


Grant
Agency: Department of Defense | Branch: Defense Advanced Research Projects Agency | Program: STTR | Phase: Phase II | Award Amount: 999.35K | Year: 2015

Recent advances in mammalian artificial chromosome design and engineering offer an alternative to existing methodologies for cellular bioengineering and address unmet needs to bioengineer more complex functionalities into human cells for subsequent commercialization. In this ST13B-001 application we propose to demonstrate utility of a novel chromosome-based gene delivery vehicle that is amenable to large genetic payloads while avoiding insertional mutagenesis and maintaining stable, long-term, gene expression. A cornerstone to our proposal is the utilization of a distinctive mammalian artificial chromosome technology termed Artificial Chromosome Expression System (ACE System), an autonomous chromosome-based circuit-board designed to contain approximately 70 site-specific recombination acceptor sites that can carry single or multiple copies of genes or DNA elements of interest. In Phase I of this solicitation we delivered a 144Kbp BAC containing the MCT1 genomic locus onto the platform ACE that had previously been loaded with a 168Kbp BAC, resulting in 312Kbp of total DNA added. In addition to demonstrating the specificity of integration we confirmed the structural stability of the genomic DNAs. In Phase II we will expand this disruptive technology by engineering additional robust and complex functionalities into the ACE system toward the goal of cell-based therapeutics.


Grant
Agency: Department of Defense | Branch: Defense Advanced Research Projects Agency | Program: STTR | Phase: Phase I | Award Amount: 100.62K | Year: 2014

Recent advances in mammalian artificial chromosome design and engineering offer an alternative to existing methodologies for cellular bioengineering and address unmet needs to bioengineer more complex functionalities into human cells for subsequent commer


Patent
Mercer University | Date: 2015-07-20

Listening lab kits are disclosed. Methods of making listening lab kits and methods of using listening lab kits are also disclosed.

Loading Mercer University collaborators
Loading Mercer University collaborators